Results 41 to 50 of about 5,163,498 (211)
Tumor inhibition by genomically integrated inducible RNAi-cassettes [PDF]
, 2006 RNA interference (RNAi) has emerged as a powerful tool to induce loss-of-function phenotypes by post-transcriptional silencing of gene expression. In this study we wondered whether inducible RNAi-cassettes integrated into cellular DNA possess the power ...
Kappel, Sven +8 more
core +1 more source
Acta Pharmaceutica Sinica B, 2019 Polo-like kinase (PLK1) has been identified as a potential target for cancer treatment. Although a number of small molecules have been investigated as PLK1 inhibitors, many of which showed limited selectivity.
Sara Abdelfatah +10 more
doaj +1 more source
SBE13, a newly identified inhibitor of inactive polo-like kinase 1 [PDF]
Journal of Cheminformatics, 2010 Poster presentation at 5th German Conference on Cheminformatics: 23. CIC-Workshop Goslar, Germany. 8-10 November 2009 Protein kinases are important targets for drug development.
Keppner Sarah +3 more
doaj +2 more sources
Relocation of Aurora B from centromeres to the central spindle at the metaphase to anaphase transition requires MKlp2 [PDF]
, 2004 Mitotic kinases of the Polo and Aurora families are key regulators of chromosome segregation and cytokinesis. Here, we have investigated the role of MKlp1 and MKlp2, two vertebrate mitotic kinesins essential for cytokinesis, in the spatial regulation of ...
Erich A. Nigg +13 more
core +1 more source
PLoS ONE, 2011 The polo-like kinase in the deep branching eukaryote Trypanosoma brucei (TbPlk) has many unique features. Unlike all the other polo-like kinases known to associate with the nucleus and controlling both mitosis and cytokinesis, TbPlk localizes to the ...
Lu Sun, Ching C Wang
doaj +1 more source
Polo-like kinase 1 as target for cancer therapy
Experimental Hematology & Oncology, 2012 Polo-like kinase 1 (Plk1) is an interesting molecule both as a biomarker and as a target for highly specific cancer therapy for several reasons. Firstly, it is over-expressed in many cancers and can serve as a biomarker to monitor treatment efficacy of ...
Weiß Lily, Efferth Thomas
doaj +1 more source
Identification of Plk1 type II inhibitors by structure-based virtual screening [PDF]
, 2009 Protein kinases are targets for drug development. Dysregulation of kinase activity leads to various diseases, e.g. cancer, inflammation, diabetes. Human polo-like kinase 1 (Plk1), a serine/threonine kinase, is a cancer-relevant gene and a potential drug ...
G Schneider +7 more
core +1 more source
Identification of polo‐like kinase 1 as a therapeutic target in murine lupus
Clinical & Translational Immunology, 2022 Introduction The signalling cascades that contribute to lupus pathogenesis are incompletely understood. We address this by using an unbiased activity‐based kinome screen of murine lupus.
Yaxi Li +6 more
doaj +1 more source
A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening
Journal of Advanced Research, 2019 Polo-like kinase 1 (PLK1), a member of the Polo-like kinase family, plays an important regulatory role in mitosis and cell cycle progression. PLK1 overexpression is correlated with tumourigenesis and poor prognosis in cancer patients.
Sara Abdelfatah +3 more
doaj +1 more source
Mitotic centromere-associated kinesin (MCAK) : a potential cancer drug target [PDF]
, 2011 The inability to faithfully segregate chromosomes in mitosis results in chromosome instability, a hallmark of solid tumors. Disruption of microtubule dynamics contributes highly to mitotic chromosome instability.
Yuan, Juping +4 more
core +1 more source